These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 10738843

  • 1. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR.
    Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
    [Abstract] [Full Text] [Related]

  • 2. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, Atzeni R, Fogliani V, Giura R, Paradisi F.
    Drugs Exp Clin Res; 1999 Mar; 25(6):243-52. PubMed ID: 10713862
    [Abstract] [Full Text] [Related]

  • 3. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C, Belgian Multicenter Study Group.
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [Abstract] [Full Text] [Related]

  • 4. [Tolerance and safety of carbapenems: the use of meropenem].
    Lizasoaín M, Noriega AR.
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074
    [Abstract] [Full Text] [Related]

  • 5. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI, Fung CP, Liu CY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE.
    Surg Infect (Larchmt); 2005 May; 6(3):269-82. PubMed ID: 16201937
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing LO, Nyström PO, Anséhn S, Bäckstrand B, Skau T.
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ.
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL, Smith JW, Geckler RW, Wilson SE.
    South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.